|
|
|
|
The cardiovascular phenotype: Impact on choice of glucose-lowering therapy
|
|
|
|
|
|
|
|
نویسنده
|
kalra s. ,gupta y. ,kishor k.
|
|
منبع
|
journal of the pakistan medical association - 2016 - دوره : 66 - شماره : 4 - صفحه:480 -482
|
|
چکیده
|
One of the major endpoints to be considered while choosing glucose-lowering therapy is their impact on cardiovascular outcomes. as a corollary,the cardiovascular health assessment of a person with diabetes informs the choice of glucose-lowering treatment. the clinical aspects included in this bidirectional relationship are described in this review as the cardiovascular phenotype. vital signs,cardiac autonomic function,myocardial health and coronary status influence,and are influenced by,choice of glucose-lowering therapy. such therapy also has an impact on cerebrovascular and peripheral arterial health.these aspects shouldbe considered while planning treatment for type 2 diabetes mellitus. © 2016,pakistan medical association. all rights reserved.
|
|
کلیدواژه
|
Acarbose; Cardiovascular outcome trials; Cardiovascular Phenotype; Diabetes; Dyslipidaemia; Empagliflozin; Metformin; Obesity; Overweight
|
|
آدرس
|
department of endocrinology,bharti hospital,karnal, India, department of endocrinology,aiims,new delhi, India, department of cardiology,cygnus hospital,karnal, India
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|